StemCell Therapy

The findings were made based on a large-scale clinical trial conducted last May, involving more than 3,000 migrant workers living in Tuas South Dormitory in the Industrial District of Singapore, Channel News Asia reported.

During the six-week trial, workers were given a povidone-iodine throat spray, which can be bought off the counter, and oral hydroxychloroquine, which requires a prescription.

Both were found to reduce the incidence of coronavirus infection, according to the study.

This is the first study to demonstrate the benefits of prophylactic, or preventive therapy with either oral hydroxychloroquine or povidone-iodine throat spray in reducing SARS-CoV-2 infection among quarantined individuals living in a closed and high exposure setting," said lead author of the clinical study, Associate Professor Raymond Seet from the National University Hospital (NUH).

The two drugs were chosen because they are easily available, said Dr Seet. He also noted that they protect the throat, the key entry" for viruses.

He was presenting the study at the National University Health System and was accompanied by co-investigators Professor Paul Tambyah, Associate Professor Mikael Hartman, Associate Professor Alex Cook and Assistant Professor Amy Quek.

The findings have been published in the International Journal of Infectious Diseases.

A total of 3,037 asymptomatic healthy men aged between 21 and 60 were involved in the trial on a voluntary basis.

Participants were excluded if they had any symptoms of respiratory illnesses like fever, cough or loss of smell a month before the start of the trial. Those who had previous COVID-19 infection were also not included.

Enrolment took place in May last year amid a "slow but steady increase in (COVID-19) numbers", at the dormitory, Dr Seet said.

It was publicised to dormitory residents from countries like India, Bangladesh, China and Myanmar.

A translator had explained the study protocol, highlighting the voluntary basis of participation.

The povidone-iodine throat spray had to be used thrice a day. After six weeks, more than half of the participants had tested positive for COVID-19.

But among those who used the throat spray, only 46 per cent contracted the disease. This is compared to 49 per cent among those who took hydroxychloroquine and 70 per cent who took vitamin C.

We concluded that povidone-iodine throat spray was associated with a statistically significant reduction in infection by an absolute risk of reduction of 24 per cent while oral hydroxychloroquine was associated with a statistically significant reduction in infection by an absolute risk of reduction of 21 per cent," the channel quoted Dr Seet as saying.

This was after adjustments were made for "potential confounders", like nationalities and compliance to medications.

"This is a very simple intervention with virtually minimal side effects where we could actually cut the transmission rates in a meaningful way," Dr Hartman said.

The drugs can complement other preventive measures in high-risk settings, said researchers.

"Such settings include cruise ships, prisons, refugee camps and meat processing facilities, where there may be a pressing need for additional means to prevent spread," Dr Seet said.

Prof Tambyah gave the example of an outbreak in a nursing home.

"It's not something we are recommending across the board If there's an outbreak, then certainly that is something that's worth considering," he said.

Researchers stressed that the drugs are not meant to be used for COVID-19 prevention in the general community if it is a lower-risk setting.

The coronavirus has so far claimed 30 lives in Singapore along with 60,966 confirmed cases, according to Johns Hopkins University.

This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

More here:
Throat spray, oral drug for malaria-arthritis effective in reducing spread of Covid-19: Study - Mint

As the United States looks to combat vaccine hesitancy, at least one group is feeling even more confident in a vaccinebut not the COVID-19 shot: Patients with autoimmune rheumatic diseases (ARDs) had a higher rate of flu vaccinations during the pandemic, researchers discovered.

A total of 1,015 patients were interviewed. A greater proportion of patients received the flu shot during the pandemic (2020-21 season) than before (2019-20 season). Fewer than 1% of patients who got the shot reported disease flares.

In the pre-pandemic period, patients were more likely to say their rheumatologist did not recommend the shot compared to during the pandemic. During both flu seasons, other reasons patients skipped out on the shot included they didnt think it would have any benefit, they didnt feel it was safe, and other.

Another study analyzed the prevalence of and risk factors for venous thromboembolism (VTE) in patients with psoriasis and psoriatic arthritis (PsA). Final analysis included 2,433 patients, and there were 26 incident VTEs. The incident rate of the first VTE was 12 events per 10,000 patient-years. By age 80, 4.6% of patients had developed their first VTE. Factors independently correlated with VTE were older age, diabetes mellitus, and corticosteroid usage.

Finally, a study compared golimumab treatment retention among patients with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), and PsA. Compared to patients with RA, those with AxSpA or PsA had higher rates of retention. Further, retention rates were higher when golimumab was a first-line treatment instead of third or later. Use as first-line biological therapy, having AxSpA or PsA (instead of RA), and concomitant methotrexate therapy were all correlated with increased golimumab retention, while steroid use reduced retention.

In Case You Missed It

Flu Shot Rates Increased During COVID-19 Pandemic among Patients with Autoimmune Rheumatic Diseases

Risk Factors for VTE in Patients with Psoriasis, Psoriatic Arthritis

Golimumab Treatment Retention Comparison: RA, AxSpA, and PsA

Here is the original post:
Rheum Round-up: More Rheumatic Pts Got Flu Shot, VTE in PsA, and more - DocWire News

A roundup of some of the most popular but completely untrue stories and visuals of the week. None of these are legit, even though they were shared widely on social media. The Associated Press checked them out. Here are the facts:

___

Posts misrepresented a report from Israel on shingles cases

CLAIM: Herpes, shingles may be a side effect of the COVID-19 vaccine.

THE FACTS: Social media posts misrepresented a report from doctors in Israel. The report from researchers at the Tel Aviv Medical Center and Carmel Medical Center describes six mostly mild cases of shingles, also known as herpes zoster, that occurred shortly after vaccination with one or two doses of the Pfizer COVID-19 vaccine. The six cases were from among 491 women with rheumatoid arthritis or related disorders who received the vaccine. The report did not establish a definite link between shingles and the vaccine. Shingles is caused by the reactivation of the virus that causes chickenpox in people who had the childhood disease. The chickenpox virus, varicella-zoster, is one of several herpes viruses. A different herpes virus causes cold sores and herpes. The report was published two weeks ago in the journal Rheumatology. Social media users subsequently posted misleading claims that the COVID-19 vaccine may cause herpes, a sexually transmitted infection. Wow, whats next? Now they given people Herpes? an Instagram user falsely wrote. In their report, the researchers said the report wasnt designed to determine if the vaccine was triggering shingles the numbers were too small, and people with rheumatoid arthritis who hadnt been vaccinated werent included. Further monitoring is warranted, they wrote. Our report does not establish any causality or definite link but draws the attention to a possible association between mrna COVID-19 vaccine and herpes zoster, Dr. Victoria Furer, lead author of the report and rheumatologist at the Tel Aviv Medical Center, told the AP in an email. Dr. William Schaffner, an infectious disease expert at Vanderbilt University, said U.S. reporting on vaccine side effects hasnt shown an increase in shingles among people whove gotten a COVID-19 vaccine. Change can happen, but at the moment, U.S. surveillance systems do not indicate that shingles is occurring more frequently in the vaccinated than in the unvaccinated population, he said. Older people and those with weakened immune systems are at higher risk for shingles, Schaffner explained. While shingles can occur at any age, chances increase after age 50. The six cases were ages 36 to 61. We have been emphasizing the vaccination of older adults, Schaffner said. Thats the very population in which shingles is the most common, and so you would expect some cases of shingles to occur after vaccination because its going to occur anyway.

Associated Press writer Arijeta Lajka in New York contributed this report

___

Study lacks evidence on masks, isnt linked to Stanford

CLAIM: A Stanford University study published on the National Institutes of Health website proves face masks are absolutely worthless against COVID-19.

THE FACTS: Websites and social media users ranging from political candidates to health influencers are falsely claiming a study published on a digital research repository came from Stanford University and proves face masks are ineffective. In reality, the study is not affiliated with Stanford, nor is the author. The study is based on debunked claims about face masks, including the false notion that wearing a face covering decreases oxygen levels and increases carbon dioxide levels. Stanford peer review study on masks says they basically do not work for C-19, the local North Dakota TV show POVNow posted on Facebook on April 19. A recent Stanford study released by the NCBI, which is under the National Institutes of Health, showed that masks do absolutely nothing to help prevent the spread of COVID-19 and their use is even harmful, read a story on the conservative website The Gateway Pundit. The story was shared widely on Facebook and Twitter last week, including by Josh Mandel, a Republican U.S. Senate candidate in Ohio. The study, titled Facemasks in the COVID-19 era: A health hypothesis, makes a variety of claims about negative health impacts of masks, including the false claim that wearing a face mask restricts breathing, leading to the conditions hypoxemia and hypercapnia. Many doctors have taken to social media to debunk claims about oxygen levels and masks, and The Associated Press also has previously debunked false claims about health risks. The study also claims there is a lack of evidence for the effectiveness of face masks in preventing the spread of COVID-19. In fact, a recent study added strong evidence that statewide mask mandates slow the spread of the coronavirus. Research shows masks block virus particles from spreading from infected people who wear them, and can even provide some protection to uninfected people who wear them. The study circulating online last week was first published in November in the journal Medical Hypotheses, which writes that its purpose is to publish interesting theoretical papers. Articles submitted to the journal are not meant to prove findings using primary data, but instead to advance hypotheses. The journal has a long history of publishing fringe science and hypotheses, according to David Gorski, a surgical oncologist who blogs about medical misinformation. The studys author, Baruch Vainshelboim, is listed in the study as being affiliated with the cardiology division at the Veterans Affairs Palo Alto Health Care System/Stanford University. However, a representative for the VA Palo Alto Health Care System told the AP in an email that Vainshelboim does not work there. I can confirm this person is not one of our physicians, wrote Michael Hill-Jackson, a public affairs specialist with the system. I do not see him in our system and our Cardiology team has never heard of him. Vainshelboim also does not work for Stanford, according to Julie Greicius, senior director of external communications for the universitys medical school. Stanford University has never employed Baruch Vainshelboim, Greicius wrote in an email to the AP. Several years ago (2015), he was a visiting scholar at Stanford for a year, on matters unrelated to this paper. Vainshelboim, who lists himself on LinkedIn as a clinical exercise physiologist and does not list any current employment, did not respond to a request for comment.

Associated Press writer Ali Swenson in Seattle contributed this report.

__

Vaccinated people can participate in Red Cross blood drives

CLAIM: The Red Cross wont accept plasma donations from people who have had a COVID-19 vaccine.

THE FACTS: The American Red Cross is accepting blood and plasma donations from those who have received COVID-19 vaccines. The Red Cross states that in most cases there is no need for donors to wait to give blood, which includes plasma, after receiving a COVID-19 vaccine as long as a donor is symptom free and feeling well. Blood donors should, however, be able to provide the name of the manufacturer of the vaccine they received when donating. Yet as more and more Americans receive COVID-19 vaccines, posts online are falsely claiming that vaccinated Americans can no longer donate plasma. The posts are part of a larger misinformation effort to falsely suggest the vaccines are dangerous. The red cross wont accept plasma donations from people who have had the covid-19 vaccine, say posts that were shared on Facebook and Twitter. Youre willing to put something in your body that is so untested that the FDA and Red Cross dont know if you can donate Plasma, yet me not wanting to take it makes me irresponsible? In fact, the posts are misstating new eligibility directives for donating convalescent plasma, which is plasma from recovered COVID-19 patients used to treat others with the illness. The Red Cross once had a dedicated program collecting convalescent plasma, but that program ended on March 26. The change happened after the U.S. Food and Drug Administration updated guidance to ensure that donations from vaccinated people would contain the antibodies needed for the convalescent plasma to be useful in treating COVID-19 patients. The Red Cross acknowledges that the U.S. Food and Drug Administration did update its guidance regarding convalescent plasma donor eligibility related to those who receive a COVID-19 vaccine, the Red Cross says on their website. We are evaluating the feasibility and timeline to implement this complex update, alongside the evolving hospital needs for COVID-19 patients. The Red Cross, however, continues to accept blood donations from people regardless of their vaccine status. All blood collected through those donations is tested for COVID-19 antibodies in case it can be used for convalescent plasma to treat patients. Due to the pandemic, the Red Cross has reported a decline in blood drives, which has created more demand for blood donations.

Associated Press writer Beatrice Dupuy in New York contributed this report.

___

Photo manipulated to make Bill Clinton appear ill

CLAIM: Photo shows former President Bill Clinton looking frail and sick, showing what happens when you sell your soul.

THE FACTS: A Facebook post shared thousands of times this week compares an official White House photo of Clinton in 1993 to a more recent photo that has been edited to make the skin around his eyes red and his irises brown. This is what happens when you sell your soul, text on the post reads. Commenters on the post likened the 74-year-old former president to Satan and speculated that he had been using drugs. A reverse-image search reveals the photo in which Clinton looks ill is not genuine. Its an edited version of a 2014 photo that appears on Getty Images, taken by photographer John Lamparski. Clinton was photographed at a Christmas benefit event in New York, according to the original photos caption. In the original photo, Clintons eyes are bright blue and the skin under his eyes is not red. Internet users have previously edited this image of Clinton to make him look like he is suffering from a debilitating disease. The manipulated images have circulated so often that the online meme dictionary Know Your Meme identifies it as a common photoshop meme that it dubs AIDS Bill Clinton or Terminally Bill.

Ali Swenson

___

Vaccine not related to Danish health officials collapse on camera

CLAIM: Video shows Denmarks top health official fainting from her COVID-19 vaccine.

THE FACTS: One of Denmarks top health officials, Tanja Erichsen, collapsed during an April 14 press conference to discuss the countrys decision to discontinue use of the AstraZeneca vaccine, but it was not related to the vaccine. She had not yet been vaccinated against the disease when she fell. The video showing the collapse of Erichsen, acting director of pharmacovigilance at the Danish Medicines Agency, is being misrepresented by anti-vaccine proponents to falsely claim that she fainted as a result of receiving the AstraZeneca shot. Her fall received international press coverage that day, but footage from the video was picked up and circulated online with the false description of what happened. Literally Denmarks top health official fainting from the COVID-19 shot, claimed one Instagram post that shared the video. Shortly after Erichsens fall, Danish Health Authority Director General Soeren Brostroem told reporters at the conference that she was OK. He said she blacked out from overwork and standing too long. A spokesperson for the Danish Medicines Agency, Kim Voigt strm, told the AP that Erichsen had yet to receive a COVID-19 vaccine despite what the posts online say. Erichsen tweeted on April 19 to say that she was feeling well and to thank everyone for their concern. Denmark has primarily relied on vaccines made by Pfizer and Moderna and will continue to use those vaccines rather than AstraZeneca. The decision to discontinue AstraZeneca came after reports of rare blood clots in some recipients.

Beatrice Dupuy

___

Photo shows art piece, not lions mane mushrooms

CLAIM: Photo shows lions mane mushrooms growing in a swamp.

THE FACTS: An image viewed more than 150,000 times on Facebook last week claims to show Lions Mane mushrooms growing from a swamp but it actually shows a work of art. Lions mane mushrooms also known as bearded tooth fungus are white with long, hanging spines, similar to the figure in the picture. They are typically about the size of a football, according to British conservation charity The Woodland Trust. A reverse-image search finds the viral image shows no fungus. Instead, its an art piece made and first exhibited in 2013 by the artist Susi Brister. The work titled 613 Silky Straight in Swamp shows a platinum blonde swamp creature slowly moving through a swampy habitat, Brister told the AP in an email. To create the image, a human model posed inside a suit created from about 100 custom-made platinum blonde hair extensions, Brister wrote. The piece is part of a larger series called Fantastic Habitat, Brister wrote, in which I create and photograph sculptural coverings worn by models in the landscape that highlight both the strange confluence and disconnection between nature and artificial nature. The work was first exhibited at Lawndale Art Center in Houston. It later appeared in other galleries in Houston and Austin, Texas. It is in no way depicting a mushroom, Brister wrote. In fact, Ive never even heard of a lions mane mushroom before, but happy to have learned something new!

Ali Swenson

___

Find AP Fact Checks here: https://apnews.com/APFactCheck

___

Follow @APFactCheck on Twitter: https://twitter.com/APFactCheck

Read this article:
NOT REAL NEWS: A look at what didn't happen this week - Associated Press

American TV watchers were bummed on Monday when Carrie Ann Inaba, the well-known Dancing With the Stars judge and co-host of The Talk, announced she was taking a break from the afternoon chat show to deal with various health challenges, including an autoimmune condition known as Sjogren's syndrome.

Inaba's announcement was surprising, yet sadly familiar, as autoimmune disorders like lupus have increasingly become part of the public conversation in recent years; singer Selena Gomez and TV host Nick Cannon have both disclosed they suffer from that condition. Six years ago, Inaba was diagnosed with Sjogren's, an incurable immune disorder that can cause pain and fatigue. She also reportedly lives with spinal stenosis, a narrowing of the spinal canal that can cause pain and numbness, and the nerve disorder fibromyalgia.

Autoimmune disorders include a wide spectrum of issues caused when the immune system overreacts by attacking the body's own tissue. Women are more likely than men to be affected. Here are the most common signs that you're suffering from the most common autoimmune conditions. Read onand to ensure your health and the health of others, don't miss these Sure Signs Your Illness is Actually Coronavirus in Disguise.

"The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling," says the U.S. National Library of Medicine. Autoimmune diseases can affect the muscles, leading to aches that feel like you've overdone it at the gym even if you haven't left the couch.

This may be a sign of rheumatoid arthritis, a common autoimmune disorder caused when the immune system attacks the linings of the joints, causing painful swelling. Smaller joints tend to be affected first, followed by larger joints. But about 40 percent of people affected by rheumatoid arthritis experience symptoms that don't involve the joints at all. "In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels," says the Mayo Clinic.

According to the Mayo Clinic, Sjogren's syndrome is most commonly signified by dry eyes and a dry mouth, which occurs when the disorder affects the mucous membranes, drying them out. Sjogren's is often accompanied by other immune system disorders such as rheumatoid arthritis or lupus. People with Sjogren's might also experience joint pain or stiffness or swollen glands.

The experts at Johns Hopkins Medicine say that fatigue is a common symptom of autoimmune disease. "If you've been healthy and suddenly you feel fatigue or joint stiffness, don't downplay that," says Ana-Maria Orbai, M.D., M.H.S., a rheumatologist at the Johns Hopkins Arthritis Center. "Telling your doctor helps him or her to look closer at your symptoms and run tests to either identify or rule out autoimmune disease."

RELATED: The #1 Cause of Heart Attack, According to Science

Skin issues are a common sign of autoimmune disorders. A red rash on the skin, known as the "butterfly rash" is often found in lupus. In the skin condition known as psoriasis, the body's skin-production cells go into overdrive; this can cause rough, red patches or silvery scales on the skin as cells are produced faster than the body can shed them naturally. A related condition is psoriatic arthritis, in which joint pain, redness and swelling accompany the skin scaling. This is treatable with medication. Contact a medical professional if you have any of these symptoms, and to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Here is the original post:
Signs You Have an Autoimmune Disease, Like Carrie Ann Inaba | Eat This Not That - Eat This, Not That

A new report titled, Global Rheumatoid Arthritis Drug Market Professional Report 2021-2025 has been added by Garner Insights in its database of research reports. The scope of the report includes a comprehensive study of global, regional, and local markets for different segments of the market. The study provides complete details about the usage and adoption of Rheumatoid Arthritis Drug in various industrial applications and geographies. This helps the key stakeholders in knowing about the major development trends, growth strategies, investments, vendor activities, and government initiatives. Moreover, the report specifies the major drivers, restraints, challenges, and lucrative opportunities that are going to impact the growth of the market.

Section (2 3): Manufacturer Detail: AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, Roche, UCB, Johnson & Johnson

Request Sample Report of Global Rheumatoid Arthritis Drug Market @https://garnerinsights.com/Global-Rheumatoid-Arthritis-Drug-Market-Report-2020#request-sample

This report forecasts revenue growth at the global, regional, and local levels and provides an analysis of the most recent industry trends from 2021 to 2025 in each of the segments and sub-segments. In addition, the report highlights the impact of COVID-19 on the Global Rheumatoid Arthritis Drug Market. Some of the major geographies included in the market are given below:

Section 4: Region Segmentation: North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Section (5 6 7) :Product Type Segmentation: BiopharmaceuticalPharmaceuticals

Industry Segmentation: PrescriptionOver-the-Counter (OTC)

Grab Your Report at an Impressive Discount! Please click Here@ https://garnerinsights.com/Global-Rheumatoid-Arthritis-Drug-Market-Report-2020#discount

Table of Contents: Section 1 Rheumatoid Arthritis Drug Product Definition

Section 2 Global Rheumatoid Arthritis Drug Market Manufacturer Share and Market Overview2.1 Global Manufacturer Rheumatoid Arthritis Drug Shipments2.2 Global Manufacturer Rheumatoid Arthritis Drug Business Revenue2.3 Global Rheumatoid Arthritis Drug Market Overview2.4 COVID-19 Impact on Rheumatoid Arthritis Drug Industry

Section 3 Manufacturer Rheumatoid Arthritis Drug Business Introduction3.1 AbbVie Rheumatoid Arthritis Drug Business Introduction3.1.1 AbbVie Rheumatoid Arthritis Drug Shipments, Price, Revenue and Gross profit 2015-20203.1.2 AbbVie Rheumatoid Arthritis Drug Business Distribution by Region3.1.3 AbbVie Interview Record3.1.4 AbbVie Rheumatoid Arthritis Drug Business Profile3.1.5 AbbVie Rheumatoid Arthritis Drug Product Specification

3.2 Boehringer Ingelheim Rheumatoid Arthritis Drug Business Introduction3.2.1 Boehringer Ingelheim Rheumatoid Arthritis Drug Shipments, Price, Revenue and Gross profit 2015-20203.2.2 Boehringer Ingelheim Rheumatoid Arthritis Drug Business Distribution by Region3.2.3 Interview Record3.2.4 Boehringer Ingelheim Rheumatoid Arthritis Drug Business Overview3.2.5 Boehringer Ingelheim Rheumatoid Arthritis Drug Product Specification

3.3 Novartis Rheumatoid Arthritis Drug Business Introduction3.3.1 Novartis Rheumatoid Arthritis Drug Shipments, Price, Revenue and Gross profit 2015-20203.3.2 Novartis Rheumatoid Arthritis Drug Business Distribution by Region3.3.3 Interview Record3.3.4 Novartis Rheumatoid Arthritis Drug Business Overview3.3.5 Novartis Rheumatoid Arthritis Drug Product Specification

3.4 Regeneron Pharmaceuticals Rheumatoid Arthritis Drug Business Introduction3.5 Pfizer Rheumatoid Arthritis Drug Business Introduction3.6 Bristol-Myers Squibb Company Rheumatoid Arthritis Drug Business Introduction

Section 4 Global Rheumatoid Arthritis Drug Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.1.2 Canada Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.2 South America Country4.2.1 South America Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3 Asia Country4.3.1 China Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3.2 Japan Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3.3 India Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3.4 Korea Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4 Europe Country4.4.1 Germany Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.2 UK Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.3 France Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.4 Italy Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.5 Europe Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.5 Other Country and Region4.5.1 Middle East Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.5.2 Africa Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.5.3 GCC Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.6 Global Rheumatoid Arthritis Drug Market Segmentation (Region Level) Analysis 2015-20204.7 Global Rheumatoid Arthritis Drug Market Segmentation (Region Level) Analysis

Section 5 Global Rheumatoid Arthritis Drug Market Segmentation (Product Type Level)5.1 Global Rheumatoid Arthritis Drug Market Segmentation (Product Type Level) Market Size 2015-20205.2 Different Rheumatoid Arthritis Drug Product Type Price 2015-20205.3 Global Rheumatoid Arthritis Drug Market Segmentation (Product Type Level) Analysis

Section 6 Global Rheumatoid Arthritis Drug Market Segmentation (Industry Level)6.1 Global Rheumatoid Arthritis Drug Market Segmentation (Industry Level) Market Size 2015-20206.2 Different Industry Price 2015-20206.3 Global Rheumatoid Arthritis Drug Market Segmentation (Industry Level) Analysis

Section 7 Global Rheumatoid Arthritis Drug Market Segmentation (Channel Level)7.1 Global Rheumatoid Arthritis Drug Market Segmentation (Channel Level) Sales Volume and Share 2015-20207.2 Global Rheumatoid Arthritis Drug Market Segmentation (Channel Level) Analysis

Section 8 Rheumatoid Arthritis Drug Market Forecast 2020-20258.1 Rheumatoid Arthritis Drug Segmentation Market Forecast (Region Level)8.2 Rheumatoid Arthritis Drug Segmentation Market Forecast (Product Type Level)8.3 Rheumatoid Arthritis Drug Segmentation Market Forecast (Industry Level)8.4 Rheumatoid Arthritis Drug Segmentation Market Forecast (Channel Level)

Section 9 Rheumatoid Arthritis Drug Segmentation Product Type9.1 Biopharmaceutical Product Introduction9.2 Pharmaceuticals Product Introduction

Section 10 Rheumatoid Arthritis Drug Segmentation Industry10.1 Prescription Clients10.2 Over-the-Counter (OTC) Clients

Section 11 Rheumatoid Arthritis Drug Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost Overview

Section 12 Conclusion

Request customized copy of report @https://garnerinsights.com/Global-Rheumatoid-Arthritis-Drug-Market-Report-2020

Go here to read the rest:
Rheumatoid Arthritis Drug Market Share, Trends, Business Strategy and Forecast to 2025 The Courier - The Courier

The EU Biologics for Rheumatoid Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the EU Biologics for Rheumatoid Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the EU Biologics for Rheumatoid Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9938

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the EU Biologics for Rheumatoid Arthritis Treatment market covers various segmentation of the EU Biologics for Rheumatoid Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the EU Biologics for Rheumatoid Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding EU Biologics for Rheumatoid Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the EU Biologics for Rheumatoid Arthritis Treatment Market

Roche, Novartis, Biogen Idec, Pfizer, Amgen, and Sanofi Pharmaceutical to invest in these products.

EU Biologics for Rheumatoid Arthritis Treatment Market Segmentation

A. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors

View Detail [emailprotected]https://insights10.com/product/eu-biologics-for-rheumatoid-arthritis-treatment-market/

Table Of Content of EU Biologics for Rheumatoid Arthritis Treatment Market

1. EU Biologics for Rheumatoid Arthritis Treatment Market Overview..A. Market Size2. Market Growth Drivers...A. Growing capital investment from the key market playersB. Growing demand and higher acceptability for innovative therapies3. Epidemiology...A. New Prevalent Cases of Rheumatoid ArthritisB. Treated cases of Rheumatoid Arthritis with Biologic drugs4. Biologics for Rheumatoid Arthritis Treatment Market SegmentationA. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors5. Biologics for Rheumatoid Arthritis Major Drugs Market ShareA. Market Analysis, Insights and Forecast to 2028 by Revenue6. Competitive Landscape.....A. Major PlayersB. Products in Pipeline7. Key Company Profiles...A. Sanofi Pharmaceutical Company overview, Product & Services, Strategies & FinancialsB. Pfizer Inc. Company overview, Product & Services, Strategies & FinancialsC. Novartis Company Profile, Product & Services, Strategies & Financials8. Potential Growth Opportunities...A. Advancements in drug developmentB. Untapped markets in developing economies9. Factors Driving Future Growth..A. Key Industry Trends and Recent Developments in Biologics for Rheumatoid Arthritis TreatmentB. Future Opportunities10. Conclusion

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the EU Biologics for Rheumatoid Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the EU Biologics for Rheumatoid Arthritis Treatment market throughout 2019 to 2028.

More Reports

Major Depressive Disorders (MDD) Therapeutics Market Poised to Reach at High CAGR in Forecast Period 2019 to 2028EU Oral Drugs for Rheumatoid Arthritis Treatment Market Report By Sales and Revenue Analysis 2019 to 2028

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read more here:
EU Biologics for Rheumatoid Arthritis Treatment Market to Reach at High CAGR in Forecast Period 2019 to 2028 Clark County Blog - Clark County Blog

The EU Psoriatic Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the EU Psoriatic Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the EU Psoriatic Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9888

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the EU Psoriatic Arthritis Treatment market covers various segmentation of the EU Psoriatic Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the EU Psoriatic Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding EU Psoriatic Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the EU Psoriatic Arthritis Treatment Market

Psoriatic Arthritis Treatment are Astra Zeneca, Novartis, Glaxo Smith Kline, Merck & Co. Inc, Takeda Pharmaceutical Company

EU Psoriatic Arthritis Treatment Market Segmentation

A. By Drug ClassI. Non-steroidal Anti-inflammatory Drugs (NSAIDS)II. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)III. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)IV. OthersB. By Route of AdministrationI. OralII. ParenteralIII. TopicalIV. InjectableC. By Distribution ChannelI. Hospitals PharmaciesII. Retail PharmaciesIII. Online Pharmacies

View Detail [emailprotected]https://insights10.com/product/eu-psoriatic-arthritis-treatment-market-analysis/

Table Of Content of EU Psoriatic Arthritis Treatment Market

1. EU Psoriatic Arthritis Treatment Market Overview..A. Market Size2. EU Psoriatic Arthritis Treatment Growth Drivers..A. Rise in Customer Awareness and Increase Disease BurdenB. Promising Pipeline and New Product Launches3. EU Psoriatic Arthritis Treatment Market Segmentation.A. By Drug ClassI. Non-steroidal Anti-inflammatory Drugs (NSAIDS)II. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)III. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)IV. OthersB. By Route of AdministrationI. OralII. ParenteralIII. TopicalIV. InjectableC. By Distribution ChannelI. Hospitals PharmaciesII. Retail PharmaciesIII. Online Pharmacies4. EU Psoriatic Arthritis Treatment Major Market Share.A. Market Analysis, Insights and Forecast by Revenue5. Competitive LandscapeA. Major PlayersB. Products in Pipeline6. Key Company Profiles..A Novartis AG Company overview, Product & Services, Strategies & FinancialsB Glaxo Smith Kline Company overview, Product & Services, Strategies & FinancialsC Astra Zeneca Company overview, Product & Services, Strategies & Financials7. Healthcare Policies and Regulatory Landscape.A. Policy Changes and Reimbursement Scenario8. Factors Driving Market GrowthA. Key Industry DevelopmentsB. Mergers and Acquisitions9. Potential Growth OpportunitiesA. Market OpportunitiesB. Future Trends10. Conclusion

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the EU Psoriatic Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the EU Psoriatic Arthritis Treatment market throughout 2019 to 2028.

More Reports

EU Peripheral Vascular Devices Market By Study Growth Factors, Types and Applications with Forecasts 2019-2028EU Gout Therapeutics Market By Manufacturers, Types, Regions and Application and Forecast to 2028 by Global QYResearch

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read more from the original source:
EU Psoriatic Arthritis Treatment Market Segmentations by Application and Geography Trends, Growth and Forecasts to 2019 2028 Clark County Blog -...

The Global Psoriatic Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the Global Psoriatic Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the Global Psoriatic Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=5598

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the Global Psoriatic Arthritis Treatment market covers various segmentation of the Global Psoriatic Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the Global Psoriatic Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding Global Psoriatic Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the Global Psoriatic Arthritis Treatment Market

AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Novartis International AG; Eli Lilly and Company; Pfizer, Inc.; and UCB S.A.

Global Psoriatic Arthritis Treatment Market Segmentation

View Detail [emailprotected]https://insights10.com/product/psoriatic-arthritis-treatment-market-analysis-2019-to-2028/

Table Of Content of Global Psoriatic Arthritis Treatment Market

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the Global Psoriatic Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the Global Psoriatic Arthritis Treatment market throughout 2019 to 2028.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read the rest here:
Global Psoriatic Arthritis Treatment Market 2019 : Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast to...

This report contains market size and forecasts of Arthritis Monoclonal Antibodies in Global, including the following market information:Global Arthritis Monoclonal Antibodies Market Revenue, 2016-2021, 2022-2027, ($ millions)Global top five companies in 2020 (%)

The global Arthritis Monoclonal Antibodies market was valued at XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.Research has surveyed the Arthritis Monoclonal Antibodies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Download PDF Sample of Arthritis Monoclonal Antibodies Market report @ https://www.themarketinsights.com/request-sample/131486

Total Market by Segment:Global Arthritis Monoclonal Antibodies Market, By Type, 2016-2021, 2022-2027 ($ millions)Global Arthritis Monoclonal Antibodies Market Segment Percentages, By Type, 2020 (%)RemicadeHumiraEnbrelRituxanOrenciaActemraSimponiCimzia

China Arthritis Monoclonal Antibodies Market, By Application, 2016-2021, 2022-2027 ($ millions)China Arthritis Monoclonal Antibodies Market Segment Percentages, By Application, 2020 (%)Rheumatoid ArthritisOsteoarthritisPsoriatic ArthritisAnkylosing SpondylitisFibromyalgiaOthers

Global Arthritis Monoclonal Antibodies Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)Global Arthritis Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2020 (%)North AmericaUSCanadaMexicoEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesBeneluxRest of EuropeAsiaChinaJapanSouth KoreaSoutheast AsiaIndiaRest of AsiaSouth AmericaBrazilArgentinaRest of South AmericaMiddle East & AfricaTurkeyIsraelSaudi ArabiaUAERest of Middle East & Africa

Report Customization available as per requirements Request Customization@ https://www.themarketinsights.com/request-customization/131486

Competitor AnalysisThe report also provides analysis of leading market participants including:Total Arthritis Monoclonal Antibodies Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)Total Arthritis Monoclonal Antibodies Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:AbbVie IncF. Hoffmann-La Roche LtdNovartisJohnson & Johnson(Janssen)Pfizer IncMylanGenentechGSKAstraZeneca PLC

To Check Discount @ https://www.themarketinsights.com/check-discount/131486

Table of ContentChapter One: Introduction to Research & Analysis Reports

Chapter Two: Global Arthritis Monoclonal Antibodies Overall Market Size

Chapter Three: Company Landscape

Chapter Four: Market Sights by Product

Chapter Five: Sights by Application

Chapter Six: Sights by Region

Chapter Seven: Players Profiles

Chapter Eight: Conclusion

Chapter Nine: Appendix9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Table and FigureTable 1. Arthritis Monoclonal Antibodies Market Opportunities & Trends in Global Market

Table 2. Arthritis Monoclonal Antibodies Market Drivers in Global Market

Table 3. Arthritis Monoclonal Antibodies Market Restraints in Global Market

Table 4. Key Players of Arthritis Monoclonal Antibodies in Global Market

Table 5. Top Arthritis Monoclonal Antibodies Players in Global Market, Ranking by Revenue (2019)

Table 6. Global Arthritis Monoclonal Antibodies Revenue by Companies, (US$, Mn), 2016-2021

Table 7. Global Arthritis Monoclonal Antibodies Revenue Share by Companies, 2016-2021

Table 8. Global Companies Arthritis Monoclonal Antibodies Product Type

Table 9. List of Global Tier 1 Arthritis Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Arthritis Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 11. By Type Global Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027

Table 12. By Type Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2016-2021

Table 13. By Type Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2022-2027

Table 14. By Application Global Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027

Table 15. By Application Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2016-2021

Table 16. By Application Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2022-2027

Table 17. By Region Global Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027

Table 18. By Region Global Arthritis Monoclonal Antibodies Revenue (US$, Mn), 2016-2021

Table 19. By Region Global Arthritis Monoclonal Antibodies Revenue (US$, Mn), 2022-2027

Table 20. By Country North America Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2016-2021

Table 21. By Country North America Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2022-2027

Table 22. By Country Europe Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2016-2021

Table 23. By Country Europe Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2022-2027

Table 24. By Region Asia Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2016-2021 continued

About us.The Market Insights is a sister company to SI Market research and The Market Insights is into reselling. The Market Insights is a company that is creating cutting edge, futuristic and informative reports in many different areas. Some of the most common areas where we generate reports are industry reports, country reports, company reports and everything in between. At The Market Insights, we give our clients the best reports that can be made in the market. Our reports are not only about market statistics, but they also contain a lot of information about new and niche company profiles. The companies that feature in our reports are pre-eminent. The database of the reports on market research is constantly updated by us. This database contains a broad variety of reports from the cardinal industries. Our clients have direct access online to our databases. This is done to ensure that the client is always provided with what they need. Based on these needs, we at The Market Insights also include insights from experts about the global industries, market trends as well as the products in the market. These resources that we prepare are also available on our database for our esteemed clients to use. It is our duty at The Market Insights to ensure that our clients find success in their endeavors and we do everything that we can to help make that possible.

Direct ContactJessica Joyal+91-9284395731 | +91 9175986728sales@themarketinsights.com

Read more from the original source:
Analyzing Impacts Of COVID-19 On Arthritis Monoclonal Antibodies Market Effects, Aftermath And Forecast To 2026 KSU | The Sentinel Newspaper - KSU |...

The US Biologics for Rheumatoid Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the US Biologics for Rheumatoid Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the US Biologics for Rheumatoid Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=15536

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the US Biologics for Rheumatoid Arthritis Treatment market covers various segmentation of the US Biologics for Rheumatoid Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the US Biologics for Rheumatoid Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding US Biologics for Rheumatoid Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the US Biologics for Rheumatoid Arthritis Treatment Market

oche, Novartis, Biogen Idec, Pfizer, Amgen, and Sanofi Pharmaceutical

US Biologics for Rheumatoid Arthritis Treatment Market Segmentation

A. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors

View Detail [emailprotected]https://insights10.com/product/us-biologics-for-rheumatoid-arthritis-treatment/

Table Of Content of US Biologics for Rheumatoid Arthritis Treatment Market

1. US Biologics for Rheumatoid Arthritis Treatment Market Overview..A. Market Size2. Market Growth Drivers...A. Growing capital investment from the key market playersB. Growing demand and higher acceptability for innovative therapies3. Epidemiology...A. New Prevalent Cases of Rheumatoid ArthritisB. Treated cases of Rheumatoid Arthritis with Biologic drugs4. Biologics for Rheumatoid Arthritis Treatment Market SegmentationA. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors5. Biologics for Rheumatoid Arthritis Major Drugs Market ShareA. Market Analysis, Insights and Forecast to 2028 by Revenue6. Competitive Landscape.....A. Major PlayersB. Products in Pipeline7. Key Company Profiles...A. Roche Company overview, Product & Services, Strategies & FinancialsB. Pfizer Inc. Company overview, Product & Services, Strategies & FinancialsC. Novartis Company Profile, Product & Services, Strategies & Financials8. Potential Growth Opportunities...A. Advancements in drug developmentB. Untapped markets in developing economies9. Factors Driving Future Growth..A. Key Industry Trends and Recent Developments in Biologics for Rheumatoid Arthritis TreatmentB. Future Opportunities10. Conclusion

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the US Biologics for Rheumatoid Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the US Biologics for Rheumatoid Arthritis Treatment market throughout 2019 to 2028.

More Reports

Global Chronic Lymphocytic Leukemia Market By Study Growth Factors, Product Segments, Types and Applications with Market Forecast 2019-2028US Oral Drugs for Rheumatoid Arthritis Treatment Market By Application, Product Segment, Analysis and Forecast 2019-2028

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read the original here:
US Biologics for Rheumatoid Arthritis Treatment By Future Demand and Growth Analysis with Forecast 2019-2028 Clark County Blog - Clark County Blog

Psoriatic Arthritis Treatment Market Analysis 2021-2028 Report provides strategists, marketers and senior management with the critical information they need to assess the global Psoriatic Arthritis Treatment market as it emerges from the Covid 19 shut down. The impact of Coronavirus (COVID-19) on Psoriatic Arthritis Treatment has reinforced many trends already shaping the industry pre-COVID-19, There is a long-term trend towards the repositioning of players as entertainment providers on multiple platforms.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. It places the market within the context of the wider Psoriatic Arthritis Treatment market, and compares it with other markets.

The market characteristics section of the report defines and explains the market. The market size section gives the market size covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.

Get Sample Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriatic-arthritis-treatment-market-101066

Why buy this report?

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.

The Impact of Coronavirus on Psoriatic Arthritis Treatment global briefing offers a comprehensive guide to the Psoriatic Arthritis Treatment market at an international level. It looks at both global and regional level performances as well as providing category and channel analysis. It identifies the leading companies and offers strategic analysis of key factors influencing the industry, new product developments as well as future trends and prospects.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified. The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

An Overview of the Impact of COVID-19 on Psoriatic Arthritis Treatment Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

The Global Psoriatic Arthritis Treatment market 2021 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Psoriatic Arthritis Treatment market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report mainly studies the size, recent trends and development status of Psoriatic Arthritis Treatment Market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing Psoriatic Arthritis Treatment Market.

Psoriatic Arthritis Treatment Market Report Intended Audience:

Psoriatic Arthritis Treatment Market Highlights:

Psoriatic Arthritis Treatment Market Report Table Of Content:

Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

Executive Summary

Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

Key Insights

Continued

Related News:

Automotive Actuators Market Trends

Automotive Actuators Market Trends

Automotive Actuators Market Trends

Automotive Actuators Market Trends

Automotive Actuators Market Analysi

sAutomotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune 411045, Maharashtra, India.

Phone:

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email:[emailprotected]

Psoriatic Arthritis Treatment Industry | 2021 Global Market Size, Growth and Trends Analysis By COVID-19 Impact 2021-2028

Read more:
Psoriatic Arthritis Treatment Industry | 2021 Global Market Size, Growth and Trends Analysis By COVID-19 Impact 2021-2028 - Clark County Blog

Psoriatic arthritis (PsA) is a condition that can be particularly debilitating and painful, causing intense flare-ups that cause joints to be become inflamed.

This can make mobility difficult sometimes impossible. Not surprisingly, that can affect the ability to work, no matter your profession.

Although people with PsA can have long periods of remission, with few symptoms or even none, the unpredictability of the condition could require extended periods away from a job, or hinder your ability to look for employment.

According to a 2016 study, one-third of people with PsA reported missing work because of their disease, and the condition impacted their ability to work full-time.

Disability insurance may be able to replace some of that income.

Social Security Disability Income (SSDI) is a federal disability insurance benefit for those who have paid into Social Security while working.

If youre in a low-income bracket and havent paid enough into Social Security during your working years to qualify for SSDI, youre not out of luck. In that case, you may be a candidate for a different program called supplemental security income (SSI).

For both SSDI and SSI, benefits are limited to people who fall under the definition of being unable to perform substantial, gainful activity, says Liz Supinski, director of data science at the Society for Human Resource Management.

There are limits on how much a person can earn and still collect, she adds about $1,200 for most people, or around $2,000 per month for blind people.

Some people are covered by private disability insurance, typically acquired through their work, Supinski says.

Having this type of insurance doesnt disqualify you from receiving SSDI, because its usually a short-term benefit with more limited amounts. Because of that, she notes that many people use this insurance to replace income as theyre navigating through the SSDI process.

The Social Security Administration (SSA) categorizes PsA under the classification of immune system impairments, and specifically under sections 14.00D6 and 14.09 as Inflammatory Arthritis.

This encompasses a spectrum of inflammatory arthritis conditions, but all with the main challenge of limiting your movements, mainly through joint pain, swelling, and tenderness.

In addition to PsA, this description could include other conditions like inflammatory bowel disease (IBD), ankylosing spondylitis, and reactive arthritis, also known as Reiters syndrome.

The SSA evaluates the severity of the condition in order to approve disability benefits and acknowledges that your PsA may involve other systems as well, such as:

Because your disability claim is likely to include these types of concerns as well as complications of joint inflammation, its essential to have your medical paperwork together, including insights from your primary care doctor and specialists.

You can apply for disability benefits while youre still employed if your symptoms are significantly impacting your work, although most people tend to apply once theyve left a position, possibly because of their condition, says Supinski.

Whether you have PsA, a different condition, or a combination of conditions, the process for establishing a disability claim will be much more streamlined if you have a breadth of information already in place, says Michelle Ogunwole, MD, a specialist in internal medicine and research fellow at The Johns Hopkins University School of Medicine.

If youre managing multiple health issues or a chronic condition like psoriatic arthritis, its already a good idea to compile your medical info in one place, so you have it available for appointments, she says.

That will also give you insight into trends you may not have been seeing before, like possible triggers for a flare-up, she adds.

If possible, have the following information on hand:

Also, let your doctors, colleagues, and family know youll be going through the application process. The SSA gathers input from healthcare providers as well as the applicant and sometimes asks for additional information from family members and co-workers to determine if you qualify as disabled based on SSA criteria.

Claiming disability benefits can be a complex and lengthy process, but taking the time to understand the criteria used by the SSA can help you get closer to getting a claim approved.

Consider reaching out to representatives at your local SSA field office, since they can help you apply for SSDI and SSI benefits.

Make an appointment by calling 800-772-1213, or you can also complete an application online at the SSA website.

Elizabeth Millard lives in Minnesota with her partner, Karla, and their menagerie of farm animals. Her work has appeared in a variety of publications, including SELF, Everyday Health, HealthCentral, Runners World, Prevention, Livestrong, Medscape, and many others. You can find her and way too many cat photos on her Instagram.

Read the rest here:
A Guide to Disability Benefits and Psoriatic Arthritis - Healthline

TAMPA, Fla. A drug used for nearly a decade to prevent joint pain and swelling in those with arthritis could save your life from COVID-19. A new study is showing promising results with those sickest from the coronavirus.

Theres a promising drug doctors are using right now to treat the sickest of the sick. Its called Tocilizumab under the brand name Actembra.

This is basically another tool in the toolbox for us to help prevent people from getting severe COVID and die," said Dr. Michael Teng, a virologist at USF Health.

The antibody has been used to lessen the inflammation in patients with rheumatoid arthritis for nearly a decade now.

Preliminary findings of the RECOVERY Trial out of the U.K. show Tocilizumab also reduces the risk of death, shortens the amount of time someone is in the hospital and lessens the need for a ventilator.

If you get infected and have severe COVID now there's an additional drug that can help you survive," said Dr. Teng.

The same trial by the University of Oxford first discovered Dexamethasone was effective in fighting COVID.

So they've [researchers] tried things like anti-HIV drugs, which didn't work very well. They tried hydroxychloroquine and the study showed it didn't work very well," said Dr. Teng.

Dexamethasone was used on former President Donald Trump. Now it's part of standard care. Meanwhile, Tocilizumab would provide it a boost. The study shows for every 25 patients treated with the drug, one additional life would have been saved.

But is it necessary with millions of Americans now getting vaccinated? Doctor Teng insists it absolutely is necessary.

Only about 4% of our population has gotten both doses of vaccine. So that means there's a lot of people out there that are still susceptible to coronavirus infection.

Dr. Teng warns there are downsides to the drug.

It's expensive, it's not that widely available," he said.

Nonetheless, he believes, any tool to help in the fight against the pandemic is always welcome.

See original here:
Drug used to treat arthritis could save the lives of those sickest from COVID-19, study finds - ABC Action News

A study evaluated the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA), and compared outcomes between patients taking abatacept compared to other bDMARDs.

The retrospective study included patients with RA treated with abatacept as any line of therapy (LOT) at four different centers in the UK between January 2013 and December 2017.

Final analysis consisted of 213 patients who received up to eight LOTs. The mean age was 55.2 years, and most patients were female (71.4%). The median disease duration prior to initiating bDMARD therapy was 3.9 years (interquartile range, 2.1-8.5 years). Receipt of abatacept or any bDMARD was correlated with reduced six-month disease activity score for 28 joints (DAS28) erythrocyte sedimentation rate and DAS2 C-reactive protein (DAS28-CRP) scores. European League Against Rheumatism (EULAR) responses, measured as good, moderate, or no response, were better for patients when receiving abatacept compared to when receiving other bDMARDs, at six months (22.8% vs. 16.6%, 41.3% vs. 41.4%, and 35.9% vs. 42.1%, respectively) and one year (27.9% vs. 21.2%, 36.1% vs. 34.5%, and 36.1% vs. 44.2%, respectively).

The 68 patients who received abatacept as their first LOT were on treatment much longer compared to those receiving other bDMARDs (53.4 months vs. 17.4 months, P<0.01), and this was similar for the second LOT. Patients receiving other bDMARDs who stopped after six months were more likely to sustain an infection requiring antibiotics compared to patients receiving abatacept.

The study was published in BMC Rheumatology.

The researchers acknowledged the impact of the COVID-19 pandemic on treatment as well.

The rheumatology community is working to optimise disease management strategies and transition to telehealth. Early research suggests the risk of serious complications from COVID-19 is not increased for patients treated with bDMARDs or targeted synethic DMARDs. However, preventative withdrawal of these treatments, which may occur at the time of COVID-19 symptom onset, should be avoided due to the increased risk of relapse and morbidity. Future research should consider how abatacept and other bDMARDs are used in RA management during and after the pandemic, they recommended.

See the original post here:
How Does Abatacept Compare To Other bDMARDs in Rheumatoid Arthritis Treatment? - DocWire News

The medical practice group provides a non-surgical, non-opioid, outpatient pain relief program to patients around the country.

Osteoarthritis (OA) is the most common type of arthritis and affects more than 32 million adults in the United States alone. Known as the wear and tear arthritis, it occurs when the smooth cushion or the cartilage between bones breaks down, and causes joints to become painful, swollen and hard to move. The knee joint is the most common area for OA to strike and millions of people are hobbled by the debilitating pain, prohibiting them from carrying out everyday activities like climbing stairs, standing up from a seated position, or even standing for an extended amount of time.

Besides the challenge of managing the chronic pain, the consequential immobility and inactivity exacerbates other serious conditions such as obesity, diabetes, and heart disease. Arthritis Knee Pain Centers provides a comprehensive program that can help reduce pain and increase mobility without surgery or opioids.

Headquarted in Spring, Texas, Arthritis Knee Pain Centers growing network has practices all over the US. They specialize in a minimally invasive therapy designed to replenish depleted joint fluids with an FDA-approved cushioning gel. They use advanced digital imaging for precision placement, removing the guesswork that many of todays practitioners rely on to treat knee and joint pain.

Our singular clinical focus on treating osteoarthritis of the knee combined with our utilization of cutting-edge technology has allowed our specially trained physicians to excel at relieving the often debilitating chronic pain of our patients, says Dr. John J. Rush, Chief Medical Officer of Arthritis Knee Pain Centers. Weve successfully treated more than 20,000 patients since 2016.

Recognizing early warning signs of osteoarthritis can help slow down its progression. Some of its early warning signs are pain; stiffness and loss of flexibility; as well as a scraping or grating sensation when moving the knees. There are many ways that can help reduce the pain and the need for pain medication. Exercise and weight loss; physical therapy; and precision guided injections are some of the ways that can help manage osteoarthritis.

For more information on Arthritis Knee Pain Centers and osteoarthritis, visithttps://www.arthritiskneepain.com.

About Arthritis Knee Pain Centers

Arthritis Knee Pain Centers is a medical practice group that specializes in an FDA-approved pain relief therapy designed to help osteoarthritis sufferers decrease their knee joint pain. Headquartered in Spring, Texas, Arthritis Knee Pain Centers has practices in Texas, New York, Kentucky, Arizona, Ohio, North Carolina, South Carolina, and New Jersey.

Media ContactCompany Name: Arthritis Knee Pain CentersContact Person: Teresa JeffersonEmail: Send EmailPhone: 202-596-9229Country: United StatesWebsite: https://www.arthritiskneepain.com/

Read the rest here:
Arthritis Knee Pain Centers Offers Therapy That Helps Reduce Osteoarthritis Knee Pain and Increase Mobility - Press Release - Digital Journal

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.

The EC approval of Yuflyma follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in December 2020. The marketing authorisation is based on analytical, preclinical and clinical studies, demonstrating that Yuflyma is comparable to adalimumab, the reference product, in terms of safety, efficacy, PK/PD and immunogenicity up to 24 weeks1 and 1 year2 following treatment. Based on the results of the pivotal study, a high concentration formulation of Yuflyma has been approved for use in the European Union (EU), in patients with thirteen chronic inflammatory diseases; rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), paediatric plaque psoriasis (pPsO), hidradenitis suppurativa (HS), Crohns disease (CD), paediatric Crohns disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV).

In Europe, according to IQVIA data, 60% of the whole adalimumab market has been taken by high concentration formulation and over 90% of the original adalimumab market has already been replaced with a high concentration version. With high concentration, low-volume, and consequently less pain, adalimumab can improve treatment adherence at the very least. Therefore, we focused on development of a high concentration biosimilar to provide a significant alternative to the adalimumab treatment category, said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. In terms of the administration device, we have looked to ensure improved convenience for patients as well as providers with the inclusion of needle size (29G), latex-free to reduce allergy risk, and a long storage period or shelf life at room temperature for 30 days.

Professor Rieke Alten, Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik, Teaching Hospital of Charit, Berlin, Germany said, Over the past two decades, anti-tumour necrosis factor (TNF) biologics have revolutionised the management of chronic immune-mediated inflammatory diseases, but some of the features needed improvement for patients to reach their therapeutic goals. As a physician, we welcome these value-added features such as high concentration and low-volume formulations to reduce injection discomfort.

The centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. This announcement will enable affordable access to a high concentration adalimumab biosimilar, broadening treatment alternatives for patients suffering with chronic inflammatory disease including rheumatoid arthritis, psoriasis, Crohns disease and ulcerative colitis.

Celltrion will take the EC Decision Reliance Procedure (ECDRP) to minimise lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications to promote patients access to advanced therapies.

- ENDS -

Notes to Editors:

About CT-P17 (biosimilar adalimumab)

CT-P17 is the first proposed high concentration, low- volume and citrate-free adalimumab biosimilar. CT-P17 is indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohns disease (CD), paediatric Crohns disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human antitumour necrosis factor (anti-TNF) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

References

1 J. Kay., et al. (2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. Poster Presented at ACR Convergence 20202 Data on file

Read more here:
Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab,...

THE University of Glasgow is embarking on a 4.6 million, four-year research collaboration with US-based pharmaceuticals group Eli Lilly and Company to discover and validate the next generation of drug targets for immunological diseases.

Led by the universitys Institute of Infection, Immunity and Inflammation, the collaboration will work across four diseases: psoriatic arthritis, rheumatoid arthritis, fibrosis, and vasculitis.

The university said it was hoped the collaboration between its scientists and those of Lilly would help enable the identification of first-in-class therapeutics for people suffering with these devastating and costly conditions.

READ MORE:Ian McConnell: Brexit could have taken many forms. Cheshire Cat Boris Johnson chose this one

It added: Rheumatoid arthritis alone affects 0.3 per cent to 1% of people across the globe and it is estimated that, within ten years of diagnosis, 40% of people will be unable to stay in full-time work. This has major socio-economic repercussions. In the UK, this costs the NHS on average 700 million per year and indirectly costs the UK economy an estimated 8 billion per year.

University of Glasgow principal Professor Sir Anton Muscatelli said: Glasgows researchers have a vision to drive forward innovation, in order to tackle some of societys most urgent challenges. The Glasgow-Lilly collaboration is well positioned to be an inspiring example of this vision and of the exciting possibilities of industry and academia working together. I look forward to seeing this important partnership progress, advancing the next generation of first-in-class therapeutic agents and their alignment with precision medicine approaches.

READ MORE:Brexit: Ian McConnell: The inconvenient truths for think big Boris Johnson, flagged by Emmanuel Macron and Danny Blanchflower

The University of Glasgow team is led by Carl Goodyear, and includes Stefan Siebert, Mariola Kurowska-Stolarska, Neal Millar, Neil Basu and Thomas Otto.

Ajay Nirula, vice-president of immunology at Lilly, said: Lillys research efforts continue to expand beyond our own laboratories to include unique partnerships with top academic institutions such as the University of Glasgow. We look forward to collaborating closely with the scientific team at UofG to discover potential new therapies for immunological disorders.

Link:
Scottish university teams up with US pharmaceuticals giant for research on immunological diseases, including arthritis - HeraldScotland

100 types of joint pain

Arthritis is an inflammation of the joints that can cause debilitating joint pain. There are more than 100 different kinds of arthritis and related conditions.

Arthritis affects more than 50 million adults and 300,000 children in America, according to the Arthritis Foundation. The causes and treatment options available vary from one type of arthritis to another.

To find the best treatment and management strategies, its important to determine the type of arthritis you have. Read on to learn about the types and what their differences are.

Osteoarthritis (OA), also called degenerative arthritis, is the most common type of arthritis. It affects about 27 million people in the United States, according to the Arthritis Foundation.

With OA, cartilage in your joints breaks down, eventually causing your bones to rub together and your joints to be inflamed with subsequent pain, bone injury, and even bone spur formation.

It may occur in just one or two joints, on one side of the body. Age, obesity, injuries, family history, and joint overuse can raise your risk of developing it. Common symptoms include:

To learn if you have OA, your doctor will take your medical history and conduct a physical exam. They may order X-rays and other imaging tests. They may also aspirate an affected joint, taking a sample of fluid from inside to check for infection.

Rheumatoid arthritis (RA) is a type of autoimmune disease in which your body attacks healthy joint tissue. The Arthritis Foundation estimates that about 1.5 million adults in the United States have RA. Nearly three times as many women have RA than men.

Common symptoms of RA include morning stiffness and joint pain, typically in the same joint on both sides of your body. Joint deformities can eventually develop.

Additional symptoms may also develop in other parts of your body including the heart, lungs, eyes, or skin. Sjgrens syndrome frequently occurs with RA. This condition causes severely dry eyes and mouth.

Other symptoms and complications include:

Your doctor cant use any single test to determine if you have RA. To develop a diagnosis, theyll likely take a medical history, conduct a physical exam, and order X-rays or other imaging tests.

Your doctor may also order a:

These tests can help your doctor learn if you have an autoimmune reaction and systemic inflammation.

Juvenile arthritis (JA) affects about 300,000 children in the United States have JA, according to the Arthritis Foundation.

JA is an umbrella term for several types of arthritis that affect children. The most common type is juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis. This is a group of autoimmune disorders that can impact childrens joints.

JIA starts to occur in children younger than 16 years old. It can cause:

Months of aching joints, swelling, stiffness, fatigue, and fevers may indicate juvenile idiopathic arthritis.

Other less common forms of JA include:

Ankylosing spondylitis (AS) and other types are autoimmune conditions that can attack the locations where tendons and ligaments attach to your bone. Symptoms include pain and stiffness, especially in your lower back.

Your spine will likely be affected the most, as AS is the most common of these conditions. It usually affects mainly the spine and pelvis but can affect other joints in the body.

Other spondyloarthropathies can attack peripheral joints, such as those in your hands and feet. In AS, bone fusion may occur, causing deformation of your spine and dysfunction of your shoulders and hips.

Ankylosing spondylitis is hereditary. Most people who develop AS have the HLA-B27 gene. Youre more likely to have this gene if you have AS and youre Caucasian. Its also more common in men than women.

Other spondyloarthritic diseases are also associated with the HLA-B27 gene, including:

Systemic lupus erythematosus (SLE) is another autoimmune disease that can affect your joints and many types of connective tissue in your body. It can also damage other organs, such as your:

SLE is more common among women, particularly those with African or Asian ancestry. Common symptoms include joint pain and swelling.

Other symptoms include:

You may experience more severe effects as the disease progresses. SLE affects people differently, but starting treatment to try to get it under control as soon as possible and working with your doctor can help you manage this condition.

Gout is a form of arthritis caused by the accumulation of urate crystals inside your joints. High levels of uric acid in your blood may put you at risk of gout.

An estimated 3.9 percent of American adults have gout thats 5.9 percent of American men and 2 percent of American women. Age, diet, alcohol use, and family history can affect your risk of developing gout.

Gout can be incredibly painful. A joint at the base of your big toe is most likely to be affected, although it can potentially affect other joints. You may experience redness, swelling, and intense pain in your:

An acute attack of gout can come on strong within a few hours during the course of a day, but the pain can linger for days to weeks. Gout can become more severe over time. Learn more about the symptoms of gout.

Infectious arthritis is an infection in one of your joints that causes pain or swelling. The infection can be caused by bacteria, viruses, parasites, or fungi. It can start in another part of your body and spread to your joints. This kind of arthritis is often accompanied by a fever and chills.

Reactive arthritis can occur when an infection in one part of your body triggers immune system dysfunction and inflammation in a joint elsewhere in your body. The infection often occurs in your gastrointestinal tract, bladder, or sexual organs.

To diagnose these conditions, your doctor can order tests on samples of your blood, urine, and fluid from inside an affected joint.

Up to 30 percent of those with psoriasis will also have psoriatic arthritis (PsA). Usually, youll experience psoriasis before PsA sets in.

The fingers are most commonly affected, but this painful condition affects other joints as well. Pink-colored fingers that appear sausagelike and pitting and degradation of the fingernails may also occur.

The disease may progress to involve your spine, causing damage similar to that of ankylosing spondylitis.

If you have psoriasis, theres a chance you could also develop PsA. If PsA symptoms start to set in, youll want to see your doctor to treat this as early as you can.

Many other forms of arthritis and other conditions can also cause joint pain. A few examples include:

If youre experiencing joint pain, stiffness, or other symptoms, talk to your doctor. They can help diagnose the cause of your symptoms and recommend a treatment plan. In the meantime, find relief from arthritis pain naturally.

More here:
What Type of Arthritis Do You Have? Understanding Symptoms

Arthritis is a painful rheumatic condition that causes joint inflammation. There are many different types of arthritis that can affect the joints and other areas of the body and cause similar symptoms, such as pain, swelling, and stiffness.

There are more than 100 different types of arthritis. Some common types of arthritis include osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA).

Below, we explore these conditions, as well as other diseases that can present with arthritis. We also discuss potential treatment and when to seek medical guidance.

According to the Centers for Disease Control and Prevention (CDC), OA affects over 32.5 million adults in the United States.

Symptoms of OA include:

People often experience OA symptoms in the hips, hands, and knees.

The following increase the likelihood of developing OA:

Learn more about OA here.

RA is an autoimmune condition that causes painful swelling and inflammation in the joints. It typically affects the hands, wrists, and feet.

RA does not only affect joints. It can also cause problems in other organs of the body, including the heart, lungs, and eyes.

While some people experience a sustained progression of the disease, the intensity of symptoms usually comes and goes. Symptoms may include:

Another characteristic of RA is symmetrical involvement. This means pain and signs of inflammation occur on both sides of the body and in the same joints.

RA can cause lasting tissue damage, which can lead to:

Some people who have RA may also need assistance walking.

Some RA risk factors include:

Learn more about RA here.

PsA is an autoimmune condition.

Symptoms of PsA include:

PsA joint involvement is asymmetric, affecting different joints on either side of the body.

This type of arthritis can develop in people with a skin condition called psoriasis, which causes scaly, flushed, or silvery patches of skin. These patches can look different depending on a persons skin color.

Learn more about psoriasis on black skin here.

Researchers still do not fully understand what causes this form of arthritis. However, having a family history of PsA may increase a persons risk of developing this condition.

Learn more about PsA here.

Gout is a type of arthritis that causes painful swelling, often in a single joint at a time.

Symptoms of gout can flare up and go away quickly. They include:

Swelling is common in the big toe. Often, it also affects the knee or ankle joint.

A person may be at higher risk of developing gout if they:

Health conditions that may lead to gout include:

Gout may also occur due to metabolic syndrome, which is not a condition in itself. It refers to a number of characteristics, diseases, or habits that can make a person more likely to experience other health conditions, such as heart disease, stroke, or diabetes.

Learn more about gout here.

This chronic illness is an autoimmune condition that commonly affects females aged 1544 years.

Lupus is not a type of arthritis in itself. However, arthritis is one of the most common symptoms of this condition.

One symptom of lupus is the characteristic butterfly rash that can develop on the face. Other rashes can also develop on the arms, hands, and face. Rashes can worsen after sun exposure.

While symptoms may differ from person to person, they generally include:

Learn more about lupus here.

Juvenile arthritis, also known as childhood arthritis, affects children or even infants.

Symptoms of juvenile arthritis include:

There is no known cause of childhood arthritis. It appears to affect children regardless of race, age, or background.

Learn more about juvenile arthritis here.

Reaching a definitive diagnosis may take time, because many types of arthritis are similar or resemble other conditions.

Typically, a doctor will first check a persons medical and family history. They will also ask about symptoms and perform a physical exam. They may run tests such as:

Arthritis management depends on the type of arthritis. There are different forms of treatment available.

Medical treatment for arthritis may involve:

Surgery may not be necessary for everyone with arthritis. However, it can benefit certain complications of arthritis that result in malalignment of joints and functional limitations due to damaged joints. It can also help with intractable pain, which is when a person experiences pain that is difficult to treat or manage.

Common surgeries for arthritis include:

Physical therapy can be a great option for people with arthritis. It can help ease pain or increase activity.

Behavioral changes that can help with arthritis may include:

Some people find certain home remedies helpful in relieving pain and swelling from certain types of arthritis. These may include:

If a person has experienced joint symptoms that last more than 3 days, they should seek treatment from a healthcare professional.

Similarly, if a person has joint symptoms at different times within a month, they should also contact a doctor.

Medications and other treatments can help a person manage chronic symptoms, such as pain and swelling.

Pain will come and go with many types of arthritis. However, even if the pain resolves, a person should still seek treatment.

It is important to treat arthritis early. If left untreated, some types of arthritis may worsen over time and cause permanent disability.

Arthritis is a painful condition that causes joint inflammation.

Different types of arthritis can cause similar symptoms. It is vital to get the correct diagnosis, as it can help determine most effective treatment options.

The right treatment may also prevent future complications and help a person live a more active life.

Here is the original post:
Common types of arthritis: Location, causes, treatment, and more - Medical News Today

February 9, 2021

After watching a close family member suffer with rheumatoid arthritis, Vidyanand Anaparti [PhD/15] was motivated to make a difference.

In 2015, Anaparti joined Max Rady College of Medicine professor Dr. Hani El-Gabalawys research program which focuses on discovering the origins of rheumatoid arthritis. Since then, Anapartis work has been recognized and was listed as one of the Arthritis Societys Top 10 Research Advances of 2020.

I understand the pain my family member goes through every single day, said Anaparti, a postdoctoral fellow in internal medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences. If Im able to prevent at least one person from getting the condition, I will think that my research is successful.

When Anaparti joined El-Gabalawys team, he was tasked with researching the cellular switches that turn genes on and off.

Anaparti studied First Nations people, who have elevated rates of rheumatoid arthritis, to figure out what factors precede or aid in the onset of the chronic disease. One of the factors is cellular switches called microRNAs. Anaparti was interested in people who had levels of anti-citrullinated protein antibody (ACPA), a type of autoantibody whose levels are routinely measured to assess the risk of developing rheumatoid arthritis.

Anaparti found that the first-degree relatives of patients with rheumatoid arthritis have altered levels of certain microRNAs and these individuals exhibit a microRNA expression pattern similar to rheumatoid arthritis patients. Anaparti found that altered microRNA expression in ACPA-positive first-degree relatives is consistent over time and how theyre expressed varies depending on the type of immune cell.

We were able to detect these microRNAs in people years before they developed rheumatoid arthritis, Anaparti said. We have the potential to identify individuals before they become a patient.

Another discovery that Anaparti made was that the methylation, a cellular switch, of specific genes in rheumatoid arthritis patients was different from healthy people and might play a crucial role in the diseases development. He also identified that the levels of some metabolic markers are shifted in at-risk, ACPA-positive first-degree relatives of people with the chronic inflammatory disorder.

Anaparti also found that methylation and microRNAs have a direct influence on the expression of certain genes involved in rheumatoid arthritis.

He has published his findings in reputed journals, including Arthritis & Rheumatology and Arthritis Research & Therapy. His research has been funded by Research Manitoba, Arthritis Society of Canada and Health Sciences Centre Foundation.

Vidyanand is a bright and creative scientist who is meticulous in his experimental approach, El-Gabalawy said. He is an integral part of our human immunology research team and is an excellent mentor for trainees in our lab.

Using data generated from Anapartis research over the last five years, El-Gabalawys team has secured funding from the Canadian Institutes of Health Research for a project focused on rheumatoid arthritis in First Nations people that will include a clinical trial to see whether the combination of turmeric, omega-3 and vitamin D can reduce the risk of rheumatoid arthritis.

Currently in the lab, Anaparti is working on advancing his findings on microRNA by trying to understand their biological role.

The ultimate objective is to prevent people from getting rheumatoid arthritis, Anaparti said. All of this research, all of this understanding, is a step forward in the right direction.

Matthew Kruchak

Read more here:
UM Today | Rady Faculty of Health Sciences | On the path to preventing rheumatoid arthritis - UM Today